WO2024230588 - ANTI-KRAS/HLA ANTIBODIES AND USES THEREOF
National phase entry:
Publication Number
WO/2024/230588
Publication Date
14.11.2024
International Application No.
PCT/CN2024/090832
International Filing Date
30.04.2024
Title **
[English]
ANTI-KRAS/HLA ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-KRAS/HLA ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
DU, Jun
TANG, Wanbo
ZHAO, Limin
JIAO, Xin
DU, Pengfei
Priority Data
PCT/CN2023/092478
06.05.2023
CN
PCT/CN2024/084444
28.03.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4963 | |
| EPO | Filing, Examination, Granting | 96216 | |
| Japan | Filing, Examination, Granting | 4813 | |
| South Korea | Filing, Examination, Granting | 7698 | |
| USA | Filing, Examination, Granting | 32590 |
Total:
146,280
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are antibodies or antigen-binding fragments thereof that binds to a complex comprising a KRAS peptide and a MHC molecule, and the related antibody-drug conjugate (ADC) derived therefrom, chimeric antigen receptor (CAR) derived therefrom, and the uses thereof.[French]
L'invention concerne des anticorps ou des fragments de liaison à l'antigène de ceux-ci qui se lient à un complexe comprenant un peptide KRAS et une molécule MHC, et le conjugué anticorps-médicament (ADC) associé dérivé de ceux-ci, un récepteur antigénique chimérique (CAR) dérivé de ceux-ci, et leurs utilisations.